Entrada Therapeutics (TRDA) Enterprise Value (2020 - 2026)
Entrada Therapeutics' quarterly Enterprise Value came in at -$76.4 million in Q1 2026, down 12.69% year-on-year from -$87.6 million in Q1 2025, and up 16.04% quarter-over-quarter from -$91.1 million in Q4 2025.
Entrada Therapeutics has reported Enterprise Value for 7 years, with the latest figure at -$76.4 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value fell 12.69% year-over-year to -$76.4 million; the trailing twelve-month figure through Mar 2026 stood at -$76.4 million (down 12.69% YoY), and the FY2025 full-year result was -$91.1 million, up 10.04% from the prior year.
- Enterprise Value for Q1 2026 stood at -$76.4 million, up from -$91.1 million in the prior quarter.
- The five-year high for Enterprise Value was -$45.2 million in Q4 2022, with the low at -$263.9 million in Q1 2022.
- Average Enterprise Value over 5 years is -$119.4 million, with a median of -$79.7 million recorded in 2023.
- Year-over-year, Enterprise Value surged 84.49% in 2022 and sank 132.31% in 2024.
- Tracing TRDA's Enterprise Value over 5 years: stood at -$45.2 million in 2022, then slumped by 49.7% to -$67.6 million in 2023, then plunged by 49.72% to -$101.2 million in 2024, then advanced by 10.04% to -$91.1 million in 2025, then climbed by 16.04% to -$76.4 million in 2026.
- The last three Enterprise Value figures came in at -$76.4 million (Q1 2026), -$91.1 million (Q4 2025), and -$93.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Entrada Therapeutics | 295.78 Mn | 295.78 Mn | - | -76.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -76.44 Mn |
| Dec 31, 2025 | -91.05 Mn |
| Sep 30, 2025 | -93.29 Mn |
| Jun 30, 2025 | -72.48 Mn |
| Mar 31, 2025 | -67.84 Mn |
| Dec 31, 2024 | -101.21 Mn |
| Sep 30, 2024 | -78.05 Mn |
| Jun 30, 2024 | -185.25 Mn |
| Mar 31, 2024 | -68.44 Mn |
| Dec 31, 2023 | -67.60 Mn |
| Sep 30, 2023 | -51.88 Mn |
| Jun 30, 2023 | -79.74 Mn |
| Mar 31, 2023 | -227.65 Mn |
| Dec 31, 2022 | -45.16 Mn |
| Sep 30, 2022 | -215.57 Mn |
| Jun 30, 2022 | -244.25 Mn |
| Mar 31, 2022 | -263.90 Mn |
| Dec 31, 2021 | -291.06 Mn |
| Sep 30, 2021 | -122.20 Mn |
| Dec 31, 2020 | -39.05 Mn |